In today's Pharmaceutical Executive Daily, AbbVie announces a $10.9 billion agreement to acquire Apogee Therapeutics, adding a suite of clinical-stage immunology assets to its portfolio, Insilico ...
AbbVie entered into an agreement to acquire Apogee Therapeutics at a price of $135.11 for each outstanding. The deal is expected to be worth about $10.9 billion and will add Apogee’s entire pipeline ...
A multi-program CNS neuroimmune partnership pairs Insilico’s generative AI discovery workflow with SK Biopharmaceuticals’ development and commercialization infrastructure, reportedly valued up to $2.5 ...
Capvaxive uniquely adds eight adult-predominant invasive serotypes absent from other approved pneumococcal vaccines, ...
Pharmaceutical Executive: How are new vaccine technologies impacting the vaccine space? Sylvia Taylor: Vaccine technologies ...
Kardigan’s offering proposes 23.3 million shares at $14–$16, targeting ~$350 million gross proceeds and an implied ~$1.3 ...
Additive manufacturing allows pharma and biotech companies to take advantage of 3D printing technology to produce medications ...
We have entered a new era, with artificial intelligence (AI) driving one of the fastest technological transformations in ...
As Connecticut moves to rein in private equity's playbook in hospital deals, pharma and life sciences leaders face a parallel ...
Silvia Taylor of Novavax details how the company leverages its expertise in vaccine development to build partnerships across ...
Pharmaceutical Executive spoke with Lisa Bollinger, chief medical officer at Polaryx. The clinical-stage biotech focuses on ...
Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results